IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.852
EU - Europa 6.163
AS - Asia 3.185
SA - Sud America 605
Continente sconosciuto - Info sul continente non disponibili 309
AF - Africa 213
OC - Oceania 8
Totale 17.335
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.713
RU - Federazione Russa 1.400
IT - Italia 1.226
GB - Regno Unito 1.038
SG - Singapore 1.018
CN - Cina 821
IE - Irlanda 740
BR - Brasile 499
DE - Germania 417
VN - Vietnam 402
SE - Svezia 371
HK - Hong Kong 318
FR - Francia 310
FI - Finlandia 176
UA - Ucraina 168
IN - India 143
KR - Corea 141
ZA - Sudafrica 121
ES - Italia 79
BD - Bangladesh 77
CA - Canada 67
MX - Messico 44
JP - Giappone 40
TR - Turchia 40
AR - Argentina 39
NL - Olanda 39
PL - Polonia 37
IQ - Iraq 34
BE - Belgio 33
NG - Nigeria 31
AT - Austria 30
PK - Pakistan 17
CZ - Repubblica Ceca 16
UZ - Uzbekistan 16
ID - Indonesia 15
KE - Kenya 14
LT - Lituania 13
EC - Ecuador 12
IR - Iran 12
PY - Paraguay 12
MA - Marocco 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
CI - Costa d'Avorio 9
CL - Cile 9
CO - Colombia 9
JM - Giamaica 9
SA - Arabia Saudita 9
DK - Danimarca 8
EG - Egitto 8
LV - Lettonia 8
EE - Estonia 7
GR - Grecia 7
AZ - Azerbaigian 6
JO - Giordania 6
NP - Nepal 6
PH - Filippine 6
PT - Portogallo 6
TH - Thailandia 6
AU - Australia 5
BO - Bolivia 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
PA - Panama 5
PE - Perù 5
BG - Bulgaria 4
ET - Etiopia 4
GE - Georgia 4
SN - Senegal 4
TW - Taiwan 4
AL - Albania 3
IL - Israele 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
MY - Malesia 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CR - Costa Rica 2
CY - Cipro 2
DZ - Algeria 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
LU - Lussemburgo 2
NO - Norvegia 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
EU - Europa 1
Totale 17.012
Salva come PNG Salva come JPEG
Città #
Southend 848
Dallas 810
Dublin 733
Singapore 582
Fairfield 529
Ashburn 492
Chandler 443
San Jose 410
Santa Clara 390
Moscow 375
Hong Kong 304
Milan 264
Siena 233
Beijing 227
Woodbridge 225
Council Bluffs 224
Munich 222
Seattle 220
Ann Arbor 216
Houston 198
Cambridge 187
Hefei 174
Wilmington 168
Seoul 137
New York 134
Los Angeles 130
Rome 130
Ho Chi Minh City 129
Jacksonville 129
Princeton 117
Johannesburg 115
Helsinki 93
Lauterbourg 90
Hanoi 89
The Dalles 73
Bengaluru 50
São Paulo 48
Boardman 45
Málaga 44
Shanghai 44
Columbus 43
San Diego 43
Orem 42
Florence 41
Buffalo 40
San Mateo 38
London 36
Tokyo 32
Brussels 31
Frankfurt am Main 31
Redondo Beach 31
Turku 31
Warsaw 30
Abuja 29
Nanjing 29
Portsmouth 29
Nuremberg 26
Chicago 25
Lappeenranta 25
Montreal 25
Chennai 23
Dong Ket 22
Naples 22
Dearborn 21
Denver 21
Mexico City 21
Brooklyn 20
Manchester 20
Stockholm 19
Vienna 19
Figino 18
Haiphong 17
San Francisco 17
Toronto 17
Atlanta 16
Düsseldorf 16
Fremont 16
Nanchang 16
Turin 16
Phoenix 15
Rio de Janeiro 15
Brescia 14
Da Nang 14
Guangzhou 14
Poplar 14
Amsterdam 13
Changsha 13
Baghdad 12
Dhaka 12
Newark 12
Tashkent 12
Washington 12
Belo Horizonte 11
Hải Dương 11
Mumbai 11
North Bergen 11
Perugia 11
Redwood City 11
Ankara 10
Bologna 10
Totale 11.343
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 335
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 333
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 304
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 303
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 299
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 289
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 283
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 281
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 263
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 262
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 262
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 257
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 257
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 254
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 252
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 250
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 249
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 243
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 242
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 240
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 235
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 232
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 231
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 231
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 217
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 215
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 214
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 211
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 207
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 205
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 205
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 202
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 201
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 195
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 194
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 192
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 191
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 190
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 188
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 186
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 184
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 183
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 182
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 181
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 177
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 176
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 173
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 173
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 173
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 173
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 170
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 168
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 167
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 165
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 165
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 163
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 161
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 159
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 157
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 154
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 153
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 151
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 150
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 148
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 147
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 147
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 146
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 146
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 146
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 144
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 144
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 143
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 142
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 139
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 138
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 137
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 135
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 132
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 129
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 126
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 125
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 123
null 121
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 120
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 118
null 114
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 113
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 112
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 95
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 94
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 72
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 69
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 68
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 56
null 32
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 30
null 14
null 12
Totale 17.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.618
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.169 0 136 92 161 66 65 71 71 69 109 110 219
2022/20231.426 78 204 166 164 126 270 69 100 97 61 63 28
2023/20241.197 38 36 101 77 21 307 408 35 8 26 34 106
2024/20252.978 67 99 377 183 288 231 110 207 319 158 295 644
2025/20266.978 476 832 779 899 1.411 241 761 227 285 387 207 473
2026/2027361 243 118 0 0 0 0 0 0 0 0 0 0
Totale 17.335